Stock Analiz

Nrc Health NRC

Biotechnology: Commercial Physical & Biological Resarch · data as of November 13, 2026

$26.56Market cap $564M
Open the interactive analysis →

Nrc Health (NRC) is a healthcare company listed in the US with a market value of about $564M. In the twelve months to September 30, 2026 it had revenue of $144M and net income of $6M, a net margin of 4.3%.

Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is track record (4/5); the weakest is future growth (0/5).

Key numbers: a P/E of 94.3, a price to free cash flow of 30.6, 5-year revenue growth of 1% a year, a 5-year average ROIC of 30%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 30% below the current price.

About Nrc Health

Nrc Health is listed in the US and classified in biotechnology: commercial physical & biological resarch. Revenue went from $99M in 2014 to $137M in 2025, growth of about 3.0% a year. It was profitable in 10 of the last 10 years in our data.

Score: 1.8 / 5

Value1/5
Future growth0/5
Track record4/5
Financial health1/5
Shareholder returns3/5

Checks passed

  • PEG below 1.5
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%
  • Profitable 5 years in a row
  • ROE above 15%
  • Positive free cash flow
  • Pays a dividend
  • Dividend 3 years in a row

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)94.3
Forward P/E26.6
P/FCF30.6
P/S3.9
P/B—
EV/EBITDA27.2
PEG0.92
Dividend yield2.41%
FCF yield3.3%
Shareholder yield6.0%
Intrinsic value vs. price−30%

Growth and quality

Revenue growth (1 yr)-4.0%
Revenue growth (5 yrs, per year)0.6%
EPS growth (5 yrs, per year)103.0%
FCF growth (3 yrs, per year)-15.9%
Net margin (5-yr avg.)18.5%
ROIC (5-yr avg.)30.0%
Profitable years (of last 10)10
Years paying a dividend10

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$144M$137M$143M$149M$152M$148M$133M$128M$120M$118M$109M
Net income$6M$11M$25M$31M$32M$37M$37M$32M$30M$23M$21M
Free cash flow$18M$16M$19M$22M$26M$41M$37M$36M$34M$24M$23M
EPS (diluted)$0.28$0.53$1.17$1.46$1.50$1.76$1.75$1.53$1.42$1.08$0.97
Net margin4.3%8.2%17.3%20.8%21.0%25.3%27.9%25.3%25.1%19.5%18.8%
ROIC—15.6%27.9%35.3%36.6%34.6%40.4%51.2%53.5%25.1%23.6%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 1 analysts is $27.00, 2% above the current price; targets range from $27.00 to $27.00; the consensus rating is “none”; expected EPS is $0.39 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is Nrc Health’s P/E ratio?

About 94.3, based on the last twelve months of diluted earnings per share (forward P/E about 26.6).

Is Nrc Health stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 30% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Nrc Health pay a dividend?

Yes. The dividend yield is about 2.41%, and it has paid dividends for 10 years in our data.

Is Nrc Health a good stock to buy?

We do not give buy or sell advice. Nrc Health scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.